Latest Neuroendocrine tumor Stories
THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
NEW YORK, June 2 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be held on April 18-22 in Denver, Colorado. Cylene scientists will unveil the first public description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2.
Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.
THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr.
New president/CEO announces timely goals for established foundation WHITE PLAINS, N.Y., March 2 /PRNewswire/ -- Several high-profile cancers are infamous for being silent killers - but they are not the only cancers that catch victims by surprise. Carcinoid cancer can go undetected for many years.
NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F.
Patients with pancreatic cancer can now see all their physicians and receive the results of tests on the same day in the same place with the recent opening of the multidisciplinary clinic at the Elkins Pancreas Center in the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston.
- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs) EAST HANOVER, N.J., Jan.
- An armed gangster.